<DOC>
	<DOCNO>NCT02918123</DOCNO>
	<brief_summary>Phase I clinical trial evaluate safety FURESTEM-CD Inj . patient moderate severe plaque-type psoriasis injection 4weeks .</brief_summary>
	<brief_title>Safety FURESTEM-CD Inj . Patients With Moderate Severe Plaque-type Psoriasis</brief_title>
	<detailed_description>This phase 1 , single center , randomize , open label , study safety FURESTEM-CD Inj . subject moderate severe plaque psoriasis . Approximately 9~18 subject administrate FURESTEM-CD Inj . FURESTEM-CD Inj . compose allogeneic hUCB-MSC ( human Umbilical Cord Blood derived-Mesenchymal Stem cell ) . hUCB-MSCs mesenchymal stem cell umbilical cord blood . Mesenchymal stem cell well-known immunosuppression , anti-inflammatory ability capable differentiate wide range cell type . Therefore , FURSTEM-CD Inj . huge possibility cell therapy product plaque-type Psoriasis patient .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . 1965 year old ( sex ) 2 . Have diagnose plaquetype psoriasis least 6 month prior screen ( subject concurrent psoriatic arthritis [ PsA ] may enrol ) 3 . Psoriasis Area Severity Index ( PASI ) score &gt; = 12 screen 4 . BSA ( Body Surface Area ) &gt; = 10 percentage screen 5 . Have least one follow conventional systemic agent treatment psoriasis , MTX , Cyclosporine , Photochemotherapy , TNFalpha inhibitor IL12/IL23 inhibitor 6 . Subject would agree avoid prolonged sun exposure , use tan booths ultraviolet light source clinical study 7 . Subject understand voluntarily sign inform consent form 1 . Subject type psoriasis ( eg . Erythrodermic , guttate , pustular ) 2 . Have history chronic recurrent infectious disease 3 . Have receive phototherapy systemic medications/treatments within 4 week screen could affect psoriasis PASI evaluation 4 . Have use topical medications/treatments within 2 week screen could affect psoriasis PASI evaluation 5 . Have use systemic immunosuppressant within 4 week screen 6 . Have administer following biological agent could affect plaquetype psoriasis Etanercept within 4 week screen Adalimumab , alefacept , infliximab within 2 month screen Ustekinumab within 4 week screen Other investigational biological agent within 4 week screening/five halflives ( whichever longer ) 7 . Pregnant , breastfeed woman woman plan become pregnant study ( Females childbearing potential must negative urine pregnancy test screening ) 8 . Have administer type investigational drug within previous 4 week five halflives investigational agent , whichever longer 9 . Subject already take need take medicine prohibit clinical study 10 . Subject sever dyshepatia ( Creatinine value ≥ 2X Upper limit normal range screen test ) 11 . Subject severe renal dysfunction ( AST/ALT value ≥ 2X Upper limit normal range screen test ) 12 . Have receive live viral bacterial vaccination within 3 month screen 13 . Have BCG ( Bacillus CalmetteGuérin ) vaccination within 12 month screen 14 . Have transplant organ ( exception corneal transplant &gt; 3 month prior screen ) 15 . Have know malignancy history malignancy 16 . Have history hypersensitivity , heavy metal poison etc . drug compose similar component undergone allergy immunotherapy previously prevention anaphylactic reaction 17 . Have serious infection ( eg . Sepsis , pneumonia pyelonephritis ) , hospitalize receive IV antibiotic infection 2 month prior screen 18 . Positive Hepatitis B virus ( HBV ) surface antigen antiHepatitis C virus antibody screen 19 . Known substance abuse ( drug alcohol ) problem within 12 month screen 20 . Subject experienced stem cell therapy 21 . Any condition PI suspect patient unsuitable clinical</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Plaque psoriasis</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Cell therapy</keyword>
	<keyword>Furestem</keyword>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>MSC</keyword>
	<keyword>Umbilical cord blood</keyword>
	<keyword>hUCB-MSC</keyword>
	<keyword>UCB-MSC</keyword>
</DOC>